In conclusion, our data indicate that miR-652 is a novel oncomiR in prostate cancer cells, inhibiting PP2A activity, through direct targeting of the PP2A regulatory subunit, PPP2R3A. This evidence concerns the gene PTPA and prostate carcinoma.